CClinicalTrials.gg
CompletedNCT03417258FITOPOLUpdated Mar 30, 2020

Phytoestrogens and Colonic Adenomatous Polyps

An observational study in Intestinal Polyps, sponsored by University of Bari. Completed at 1 site in Italy. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by University of Bari · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
30
Ages
50 Years to 75 Years
Sex
All
01

Study summary

INTRODUCTION: The data obtained by experimental studies about the influence of phytoestrogens on colorectal cancer (CRC) have been very promising. On the other hand, clinical trials have produced conflicting results. The literature suggests that some subclasses of phytoestrogens may have protective effects against CRC and colon adenomas, but most of these results come from population studies based on the dietary intake of phytoestrogens. On these premises, it is possible to hypothesize that the variability of the data reported in the literature may be due to the fact that the real absorption of phytoestrogens (by assessing their concentration in the serum or urine) and/or the ability of the single individual of producing equol was not evaluated.

PURPOSE: In the present study, the association between the phytoestrogens intake and the prevalence of colon adenomas was evaluated not only on the basis of the simply dietary intake but also on the measurement their intestinal absorption. Moreover, a specific evaluation of equol production by the intestinal flora was performed. Finally, intestinal bacteria involved in equol production were evaluated.

Read the detailed description

MATERIALS AND METHODS: Patients with sporadic colon adenomas were enrolled in group I (case) and patients without sporadic colorectal adenomas matched for sex, age and BMI were enrolled in group II (control). All participants underwent the following evaluations: BMI, dietary history (for quantitative and qualitative analysis of dietary habits), quantitative analysis of phytoestrogens (by dietary questionnaires), medications (chronic assumption of aspirin at low doses), characteristics of the polyps (for a calculation the cancer risk), analysis of urinary excretion of phytoestrogens [by high pressure liquid chromatography (HPLC)] and intestinal flora [by mass spectrometry with Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology]. At the enrolment, patients will be invited to assume a standard quantitative of phytoestrogens at 8:00 a.am. and collect both a fecal sample and the urine of the following 24 hrs.

02

Conditions studied

  • Intestinal Polyps

Keywords

  • phytoestrogens
  • isoflavones
  • adenomatous polyps
  • microbiome
03

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients (aged between 50 and 75 years) undergoing colonoscopy within 3 months from the study evaluation.

Inclusion criteria

  • subjects of both sexes aged between 50 and 75 years
  • colonoscopy within 3 months from the study evaluation

Exclusion criteria

Exclusion Criteria:

  • age \< 50 and > 75 years
  • previous diagnosis of colon cancer or inflammatory bowel diseases (IBD)
  • Hereditary intestinal tumors (FAP, HNPCC, ...)
  • ongoing infections
  • intake, in the last 4 weeks, of drugs that alter the intestinal bacterial flora
  • creatinine clearance below 60 ml/min
  • liver failure
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with polyps

    urinary phytoestrogen excretion and intestinal microbiota evaluation

  • Patients without polyps

    urinary phytoestrogen excretion and intestinal microbiota evaluation

05

What researchers measure

Primary outcomes

  1. Phytoestrogen absorption

    It will be evaluated on the basis of their 24h urine excretion

    Time frame: one day

Secondary outcomes

  1. Intestinal microbiota

    It will be evaluated on fecal samples

    Time frame: one day

06

Study locations

1 site
  • Policlinic Hospital
    Bari, 70124, Italy
07

References and documents

Publications

  • Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S. Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr. 1995 Sep;125(9):2307-15. doi: 10.1093/jn/125.9.2307. PubMed 7666247 ↗
  • Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood). 2005 Mar;230(3):155-70. doi: 10.1177/153537020523000302. PubMed 15734719 ↗
  • Jin H, Leng Q, Li C. Dietary flavonoid for preventing colorectal neoplasms. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD009350. doi: 10.1002/14651858.CD009350.pub2. PubMed 22895989 ↗
  • Kocic B, Kitic D, Brankovic S. Dietary flavonoid intake and colorectal cancer risk: evidence from human population studies. J BUON. 2013 Jan-Mar;18(1):34-43. PubMed 23613386 ↗
  • Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002 Dec;132(12):3577-84. doi: 10.1093/jn/132.12.3577. PubMed 12468591 ↗

Study documents

  • Protocol, analysis plan and consent form · Jan 24, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03417258
Lead sponsor
University of Bari
Responsible party
Michele Barone (Researcher, University of Bari) — Principal investigator
First posted
Jan 31, 2018
Start date
Jun 15, 2016
Primary completion
Jun 15, 2017
Completion
Apr 24, 2019
Last update
Mar 30, 2020

Study contacts

Alfredo Di Leo
study chair · University of Bari

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion